Back

Additive benefits of combination ARNI and SGLT2 inhibitor therapy in real-world heart failure: a propensity-weighted analysis of 11,483 asian patients

28 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: integrating therapies and education Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Porntep Amornritvanich

Police General Hospital, Bangkok (Thailand)

6 More presentations in this session

Presentation thumbnail
Low blood pressure and the effect of SGLT2 inhibitors in heart failure with reduced ejection fraction: data from the China Cardiovascular Association Database-Heart Failure Center Registry
Doctor W. Jin (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Hyperkalemia and its outcome implications in patients with heart failure with reduced ejection fraction: results from a single-center cohort
Doctor M. Mantovani (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Efficacy of sodium–glucose cotransporter 2 inhibitors in heart failure patients with low body mass index
Doctor K. Nakamoto (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Outcomes of sacubitril/valsartan plus SGLT2 inhibitors versus SGLT2 inhibitors in heart failure with reduced ejection fraction: a propensity-matched real-world analysis
Doctor O. Alameen (Doha, QA)
Abstract Slides Video
Presentation thumbnail
Systematic review and meta-analysis of GLP-1 receptor agonists in heart failure: impact on 6-minute walk test performance
Doctor T. Christophides (Nicosia, CY)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: integrating therapies and education

The Event

Event poster

ESC Congress 2026

28 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of sacubitril/valsartan and SGLT2 inhibitors on echocardiographic response and clinical outcomes after cardiac resynchronization therapy: insights from a real-world cohort
10 May 2026
thumbnail
Congress Presentation
State-of-the-art lecture on contemporary therapy for HFrEF
28 August 2026
thumbnail
Congress Presentation
Impact of LVEF and de novo heart failure on outcomes of SGLT2 inhibitor therapy initiated during acute heart failure
11 May 2026
thumbnail
Congress Presentation
Real-world comparison between ARNI and RAS Blockade in Patients with HFrEF
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources